Toward the discovery of novel anti-HIV drugs. Second-generation Inhibitors of the cellular ATPase DDX3 with Improved anti-HIV activity: Synthesis, Structure-activity relationship analysis, cytotoxicity studies, and target validation
Maga, Giovanni Falchi, Federico Radi, Marco Botta, Lorenzo Casaluce, Gianni Bernardini, Martina Irannejad, Hamid Manetti, Fabrizio Garbelli, Anna Samuele, Alberta Zanoli, Samantha Esté, José A Gonzalez, Emmanuel Zucca, Elisa Paolucci, Stefania Baldanti, Fausto De Rijck, Jan Debyser, Zeger Botta, Maurizio # ×
Wiley - V C H Verlag GmbH & Co. KGaA
ChemMedChem vol:6 issue:8 pages:1371-1389
A hit optimization protocol applied to the first nonnucleoside inhibitor of the ATPase activity of human DEAD-box RNA helicase DDX3 led to the design and synthesis of second-generation rhodanine derivatives with better inhibitory activity toward cellular DDX3 and HIV-1 replication. Additional DDX3 inhibitors were identified among triazine compounds. Biological data were rationalized in terms of structure-activity relationships and docking simulations. Antiviral activity and cytotoxicity of selected DDX3 inhibitors are reported and discussed. A thorough analysis confirmed human DDX3 as a valid anti-HIV target. The compounds described herein represent a significant advance in the pursuit of novel drugs that target HIV-1 host cofactors.